Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to increase access to medications that treat opioid addiction.
The problem
Opioid addiction affects millions of Americans. Many people cannot access treatment medications due to regulations, costs, or lack of providers in their communities.
The proposal
The bill modernizes rules around opioid treatment programs. It likely expands who can prescribe addiction medications and removes barriers to opening treatment clinics.
The impact
People struggling with opioid addiction gain easier access to treatment. Healthcare providers can treat more patients. Communities with limited treatment options get new resources.
Expanding treatment access means more individuals with opioid addiction can receive medications that work. This saves lives and reduces overdose deaths. Removing barriers makes treatment faster and easier to find.
Treating addiction prevents expensive emergency visits and hospital stays from overdoses. Insurance companies and taxpayers save money when addiction is managed early. Productive people stay healthy and work.
Rural areas often lack addiction treatment services. Making treatment rules simpler helps doctors in small towns prescribe medications. This brings healthcare to people who need it most.
Addiction treatment helps people recover and rebuild families. Communities see less crime and homelessness. People return to work and become self-sufficient.
Expanding prescribing rights could lead to misuse if not carefully monitored. Addiction medications themselves can be abused. Weaker safeguards might put vulnerable people at risk.
New prescribers need proper training to use addiction medications correctly. The bill may not require enough education or monitoring. Poor implementation could harm patients.
Relaxed rules could attract people seeking medications for wrong reasons. Drug dealers might exploit easier access. Fraud could increase without strong enforcement.
Expanding treatment requires funding for training, monitoring, and program support. States and small clinics may struggle to afford these costs. Federal funding may not fully cover expenses.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.